AstraZeneca Ionis trial failure investigations

On July 9, 2026, AstraZeneca and Ionis Pharmaceuticals announced that the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen) for amyloid cardiomyopathy did not meet its primary endpoint. AstraZeneca's ADS fell 5.7% and Ionis's stock fell 23.9%, wiping out over $3.3 billion in market capitalization. Multiple law firms, including Pomerantz LLP, Hagens Berman, and Levi & Korsinsky, have launched investigations into whether the companies and their officers engaged in securities fraud or made insufficiently transparent statements about the trial design and data. The investigations focus on the high percentage of patients on stabilizer therapy, which may have contributed to the trial failure.